BioSpace News Archive

Growing mortality rate as a result of surging cancer cases is prompting manufacturers to develop advanced devices for early screening and detection

Electronic medical record systems, sometimes used synonymously with electronic health records systems, have gained widespread traction in medical practices across the globe.

Sleep apnea is a disorder, wherein breathing is disturbed during sleep due to oxygen insufficiency in the body and brain. This can lead to airway blockage called obstructive sleep apnea.

Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, announced that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a potential anti-resistance therapy for difficult-to-treat cancers

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reprised initial clinical results from its ongoing Phase 1/2 study of RTX-240 in advanced solid tumors at the American Association for Cancer Research (AACR) Virtual Annual Meeting.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in UPLIFT, a single-arm registration strategy to evaluate the safety and efficacy of upifitamab rilsodotin (UpRi, XMT-1536) in patients with platinum-resistant ovarian cancer

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast cancer model.

Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, will display multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021.

- The Prime Minister, Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date April 9, 2021 Time 11:30 AM (EDT) Location